David E. I. Pyott Sells 32,450 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director David E. I. Pyott sold 32,450 shares of the stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the transaction, the director now owns 136 shares in the company, valued at $30,013.84. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $247.00 on Friday. The firm has a market cap of $31.24 billion, a PE ratio of -92.16 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $252.87. The firm’s 50-day simple moving average is $157.89 and its 200-day simple moving average is $164.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. During the same quarter in the previous year, the business posted ($1.40) EPS. Alnylam Pharmaceuticals’s revenue was up 54.8% compared to the same quarter last year. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -3.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

ALNY has been the topic of a number of recent analyst reports. StockNews.com raised shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, April 29th. HC Wainwright reiterated a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday. Chardan Capital restated a “buy” rating and set a $225.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, May 3rd. Royal Bank of Canada raised their price objective on Alnylam Pharmaceuticals from $235.00 to $250.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Bank of America boosted their target price on Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the stock a “buy” rating in a report on Tuesday. Eight investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $245.14.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 0.4% during the first quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company’s stock worth $1,792,542,000 after purchasing an additional 50,366 shares during the period. Wellington Management Group LLP raised its stake in Alnylam Pharmaceuticals by 6.0% during the third quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock worth $1,139,074,000 after acquiring an additional 364,021 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Alnylam Pharmaceuticals by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after acquiring an additional 201,784 shares during the period. Capital International Investors grew its holdings in shares of Alnylam Pharmaceuticals by 1.8% during the first quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock valued at $545,674,000 after purchasing an additional 64,560 shares during the last quarter. Finally, Capital Research Global Investors raised its position in shares of Alnylam Pharmaceuticals by 7.3% during the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock worth $470,018,000 after purchasing an additional 214,908 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.